Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2022

View Archived Issues

EGFR-TKI TAS-3351 overcomes T790M and C797S mutations tied to NSCLC treatment resistance

CLN-978, a next-generation CD19-targeted therapeutic for the treatment of B-cell malignancies

Chinese investigators patent new THR-beta agonists

CJRS-10671 and CJRS-10672, biotherapeutic candidates with promising antitumor efficacy in vivo

Gilead Sciences discloses new HIV antivirals

Yonsei University presents new SLC26A4 inhibitors

Chinese researchers identify new anti-claudin18.2 ADCs

New HIF-2alpha PET tracer presented by University of Texas System

PAX8-SOX17 tandem involved in tumor angiogenesis

PKMYT1 targeting useful for the treatment of CCNE1-amplified cancers

Sex disparities of lupus recapitulated in mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...